Association of olanzapine-induced weight gain with an increase in body fat.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  American Journal of Psychiatry

• Publication date

  2001-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1176/APPI.AJP.158.10.1719PMID 11579009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Body weight and leptin plasma levels during treatment with antipsychotic drugs.

  1999cited by this paper
• Weight loss increases and fat loss decreases all-cause mortality rate: results from two independent cohort studies

  1999cited by this paper
• Novel antipsychotics: comparison of weight gain liabilities.

  1999cited by this paper
• Antipsychotic-induced weight gain: a comprehensive research synthesis.

  1999cited by this paper
• Body weight gain induced by antipsychotic drugs: mechanisms and management

  1999cited by this paper
• How to appease the appetite of psychotropic drugs.

  1998cited by this paper
• The effect of age on the association between body-mass index and mortality.

  1998cited by this paper
• Neuropharmacology of obesity: my receptors made me eat it.

  1998cited by this paper
• Serum leptin levels increase rapidly after initiation of clozapine therapy

  1998cited by this paper
• Leptin: the voice of the adipose tissue.

  1997cited by this paper
• Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability.

  1997cited by this paper
• Serum immunoreactive-leptin concentrations in normal-weight and obese humans.

  1996cited by this paper
• Olanzapine versus Placebo and Haloperidol

  1996cited by this paper
• Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.

  1996cited by this paper
• Weight gain induced by clozapine.

  1995cited by this paper
• Body composition, not body weight, is related to cardiovascular disease risk factors and sex hormone levels in men.

  1987cited by this paper

• Revolutionizing Huntington’s Disease Treatment: Breakthroughs in AAV-Mediated Gene Therapy

  2025cites this paper
• Effect of olanzapine on changes in serum complement factors levels in patients with first-episode schizophrenia

  2025influential citation
• Cell models to probe the biological bases of Antipsychotic-induced Metabolic Syndrome: towards an individual specific approach.

  2025cites this paper
• Contrasting the pharmacokinetic performance and gut microbiota effects of an amorphous solid dispersion and lipid nanoemulsion for a poorly water-soluble anti-psychotic.

  2024cites this paper
• Percent Body Fat and Weight Status of Youth Participating in Pediatric Weight Management Programs in the Pediatric Obesity Weight Evaluation Registry

  2024cites this paper
• Association of Disease Duration and Duration of Olanzapine Use with Blood Sugar, Blood Pressure, BMI, and Lipid Profile among Schizophrenic Patients in Iraq

  2023cites this paper
• The impact of common pharmaceutical excipients on the gut microbiota

  2023cites this paper
• Current and Possible Future Therapeutic Options for Huntington’s Disease

  2022cites this paper
• The role of hypothalamic endoplasmic reticulum stress in schizophrenia and antipsychotic-induced weight gain: A narrative review

  2022cites this paper
• A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine

  2021cites this paper
• Adiposity in schizophrenia: A systematic review and meta‐analysis

  2021cites this paper
• The Role of the Central and the Peripheral Neuropeptides in Weight Gain and Metabolic Changes Related to Olanzapine

  2021cites this paper
• Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review

  2020influential citation
• High fat worsens olanzapine induced metabolic abnormalities in rats

  2020cites this paper
• High prevalence of metabolic alterations in Latin American patients at initial stages of psychosis

  2019cites this paper
• The protective effect of resveratrol against risperidone-induced liver damage through an action on FAS gene expression.

  2019cites this paper
• A role of neuropeptide CART in hyperphagia and weight gain induced by olanzapine treatment in rats.

  2018cites this paper
• Functional Changes of Orexinergic Reaction to Psychoactive Substances

  2018cites this paper
• Long-term administration of olanzapine induces adiposity and increases hepatic fatty acid desaturation protein in female C57BL/6J mice

  2018cites this paper
• Prevalence and Assessment of Adverse Drug Reactions in Mental Health Institute in a Tertiary Care Teaching Hospital: A 2 Years of Cross-Sectional Study

  2018cites this paper
• An Analysis of Social Support and Weight Status among Persons Taking Antipsychotic Medications

  2018cites this paper
• Ameliorative Effect of Curcumin on Olanzapine-induced Obesity in Sprague-Dawley Rats

  2017cites this paper
• Olanzapine-induced renal damage and metabolic side effects: the protective effect of thymoquinone

  2017cites this paper
• Oral haloperidol or olanzapine intake produces distinct and region-specific increase in cannabinoid receptor levels that is prevented by high fat diet.

  2017cites this paper
• Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population‐based UK cohort study using electronic health records

  2016cites this paper
• The impact of antipsychotic drugs on the expression of genes associated with obesity

  2016cites this paper
• Atypical antipsychotics and effects on feeding: from mice to men

  2016cites this paper
• Effect of extended olanzapine administration on POMC and neuropeptide Y mRNA levels in the male rat amygdala and hippocampus

  2016cites this paper
• Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study

  2016cites this paper
• Nutrition in Cancer Care

  2016cites this paper
• Co-morbid Hypertension, Diabetes Mellitus or Dyslipidemia among Patients Prescribed with Second Generation Antipsychotic: A Comparison Study between Aripiprazole, Quetiapine and Clozapine based on Pharmacy Prescription Database

  2015cites this paper
• Atypical Antipsychotics and the Risk of Hyperlipidemia: A Sequence Symmetry Analysis

  2015cites this paper
• Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide’s antiproliferative effect

  2015cites this paper
• Atypical antipsychotics and metabolic syndrome

  2015cites this paper
• Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis.

  2015cites this paper
• Benzo- and thienobenzo- diazepines: multi-target drugs for CNS disorders.

  2015cites this paper
• Increased lean body mass as an early indicator of olanzapine-induced weight gain in healthy men

  2015cites this paper
• Salience network and olanzapine in schizophrenia: implications for treatment in anorexia nervosa.

  2015cites this paper
• A STUDY ON DRUG USE PATTERN AND ADVERSE DRUG REACTIONS OF ANTI-PSYCHIATRIC MEDICATIONS IN A PSYCHIATRY SPECIALIZED HOSPITAL Original Article

  2014cites this paper
• Molecular and cellular regulation of hypothalamic melanocortin neurons controlling food intake and energy metabolism

  2014cites this paper
• Modelling olanzapine-induced weight gain in rats.

  2014cites this paper
• Clinical Study Evaluation of Efficacy , Safety , and Cognitive Profile of Amisulpride Per Se and Its Comparison with Olanzapine in Newly Diagnosed Schizophrenic Patients in an 8-Week , Double-Blind , Single-Centre , Prospective Clinical Trial

  2014cites this paper
• An evaluation of the metabolic effects of antipsychotic medications in patients suffering from psychiatric illness

  2014cites this paper
• Quality of Life, Health Status, and Academic Success in Undergraduates

  2014cites this paper
• Neuroleptic Drugs Affect Sympathetic and Thermogenic Reactions to Orexin A

  2014cites this paper
• In Vivo Pharmacological Evaluations of Novel Olanzapine Analogues in Rats: A Potential New Avenue for the Treatment of Schizophrenia

  2013cites this paper
• AN EVALUATION OF EFFICACY AND SAFETY OF ANTIPSYCHOTIC MEDICATIONS IN PATIENTS SUFFERING FROM PSYCHIATRIC ILLNESS

  2013cites this paper
• Formation of polymeric films containing supersaturated levonorgestrel contraceptive drug by transdermal metered dose aerosol

  2013cites this paper
• The investigation of leptin and hypothalamic neuropeptides role in first attack psychotic male patients: olanzapine monotherapy.

  2013cites this paper
• Effects of olanzapine versus risperidone on body mass index, serum leptin and lipid profile in schizophrenic patients

  2013cites this paper
• The effects of psychotropic drugs on the regulation of glucose metabolism.

  2013cites this paper
• Improving health promotion in psychiatric inpatient settings

  2013cites this paper
• Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics.

  2013cites this paper
• Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia

  2013cites this paper
• Chronic olanzapine administration in rats: effect of route of administration on weight, food intake and body composition.

  2013cites this paper
• The gut microbiota as a contributing factor to antipsychotic-induced weight gain and metabolic dysfunction

  2013cites this paper
• Soccer practice as an add-on treatment in the management of individuals with a diagnosis of schizophrenia

  2013cites this paper
• Atypical antipsychotics and diabetic ketoacidosis: a review

  2013cites this paper
• Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients

  2013cites this paper
• Design, Synthesis, and Pharmacological Evaluation of Novel Antipsychotic Drugs Based on Olanzapine That Display Reduced Weight Gain and Metabolic Side Effects

  2012cites this paper
• Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment

  2012cites this paper
• Evaluation of Efficacy, Safety, and Cognitive Profile of Amisulpride Per Se and Its Comparison with Olanzapine in Newly Diagnosed Schizophrenic Patients in an 8-Week, Double-Blind, Single-Centre, Prospective Clinical Trial

  2012cites this paper
• Adverse Metabolic Effects Associated with Atypical Antipsychotics

  2012cites this paper
• The acute effects of olanzapine on ghrelin secretion, CCK sensitivity, meal size, locomotor activity and body temperature

  2012cites this paper
• Poster #13 RECEPTOR BINDING PROFILES OF ANTIPSYCHOTIC MEDICATIONS AND GLUCOSE DYSREGULATION: AN ACUTE ANIMAL MODEL

  2012cites this paper
• Are Cardiometabolic and Endocrine Abnormalities Linked to Sleep Difficulties in Schizophrenia? A Hypothesis Driven Review

  2012cites this paper
• Olanzapine and sibutramine have opposing effects on the motivation for palatable food

  2012cites this paper
• Alterations to Melanocortinergic, GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine-Induced Weight Gain

  2012cites this paper
• The Role of Leptin in Antipsychotic-Induced Weight Gain: Genetic and Non-Genetic Factors

  2012cites this paper
• Dysregulation of Adipocytokines Related to Second-Generation Antipsychotics in Normal Fasting Glucose Patients With Schizophrenia

  2012cites this paper
• Developing a rodent model for antipsychotic-induced metabolic adverse effects

  2012cites this paper
• Effects of Orally Disintegrating Vs Regular Olanzapine Tablets on Body Weight, Eating Behavior, Glycemic and Lipid Indices, and Gastrointestinal Hormones: A Randomized, Open Comparison in Outpatients with Bipolar Depression

  2011cites this paper
• Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.

  2011cites this paper
• Psychopharmaka und Diabetes

  2011cites this paper
• A Double Blind, Placebo-Controlled, Randomized Crossover Study of the Acute Metabolic Effects of Olanzapine in Healthy Volunteers

  2011cites this paper
• Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats.

  2011cites this paper
• Beneficial effect of the insulin sensitizer (HSP inducer) BGP-15 on olanzapine-induced metabolic disorders.

  2010cites this paper
• Effects of antipsychotic drugs on the expression of neurotransmitter receptors in the rat brain

  2010cites this paper
• Retrospective Comparison of Weight Gain between Olanzapine- and Risperidone-Treated Patients

  2010cites this paper
• Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance.

  2010cites this paper
• Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats.

  2010cites this paper
• ESTUDO DAS AFERÊNCIAS IMUNORREATIVAS AO HORMÔNIO CONCENTRADOR DE MELANINA (MCH) DO NÚCLEO ACCUMBENS, NO RATO LONG-EVANS (RATTUS NORVEGICUS)

  2010cites this paper
• Olanzapine increases cell mitotic activity and oligodendrocyte-lineage cells in the hypothalamus.

  2010cites this paper
• Olanzapine affects locomotor activity and meal size in male rats.

  2010influential citation
• Reducing olanzapine-induced side effects by betahistine: a study in the rat model

  2010cites this paper
• Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state.

  2010cites this paper
• Acute effects of olanzapine on behavioural expression including the behavioural satiety sequence in female rats

  2010cites this paper
• Risperidone Treatment Increases CB1 Receptor Binding in Rat Brain

  2009cites this paper
• The Role of Thermogenesis in Antipsychotic Drug‐induced Weight Gain

  2009cites this paper
• Effects of Six Second Generation Antipsychotics on Body Weight and Metabolism – Risk Assessment and Results from a Prospective Study

  2009cites this paper
• Medikamente und Diabetes

  2009cites this paper
• The neurotrophic and neuroprotective effects of psychotropic agents

  2009cites this paper
• Weight gain with antipsychotics : What role does leptin play ?

  2009cites this paper
• Obesity, serious mental illness and antipsychotic drugs

  2009cites this paper
• Physiological Aberrations in Patients with Schizophrenia

  2009cites this paper
• The Relationships of Leptin, Adiponectin Levels and Paraoxonase Activity with Metabolic and Cardiovascular Risk Factors in Females Treated with Psychiatric Drugs

  2008cites this paper
• Pharmacological Management of Atypical Antipsychotic-Induced Weight Gain

  2008cites this paper
• [Psychopharmacology and metabolic syndrome].

  2008cites this paper
• Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.

  2008cites this paper
• Comparison of clinical body composition methods in people taking weight-inducing atypical antipsychotic medications.

  2008cites this paper